EHA 2023 | Journaal Acute Myeloïde Leukemie (AML)

In dit journaal bespreekt dr. Anna van Rhenen haar selectie van het belangrijkste EHA-nieuws op het gebied van acute myeloïde leukemie. Er wordt gesproken over de stand van zaken en nieuwste ontwikkelingen van immuun- en doelgerichte therapie voor de behandeling van AML. Wat zijn de belangrijkste ontwikkelingen op het gebied van combinatiestrategieën? En er is aandacht voor risicostratificatie. 

De volgende abstracts komen in dit journaal ter sprake: 

Nieuwe therapeutische middelen

• LB2713 - Activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed/refractory NPM1-mutated AML 

• S104 - Differential target profiles and efficacy of ADCLEC.SUN1 and CD33-CARS in humanized AML models

• LB2711 - BMT-CTN 1506 (MORPHO): a randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT2-ITD AML

Combinaties van middelen

• S130 - Preliminary result of QUIWI: a double blinded, randomized clinical trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD wild-type AML 

• S131 - A randomised assessment of the sequential addition of the kinase inhibitor quizartinib to intensive chemotherapy in older acute myeloid leukaemia (AML) patients: results from the NCRI AML18 trial 

• S132 - Updated results of VEN-A-QUI study: a phase 1-2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: azacitidine or low-dase cytarabine with venetoclax and quizartinib 

• P490 - Updated survival, blood count recovery and safety results from the agile study in patients with acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine 

Risicostratificatie

• S135 - Next-generation sequencing-based measurable residual disease monitoring in acute myeloid leukemia with FLT3 internal tandem duplication treated with intensive chemotherapy plus midostaurin